Minimal residual disease in multiple myeloma

Immunoconjugates address unmet needs in Hodgkin's lymphoma patients

EHA 2015: Expert opinions on new treatment standard in multiple myeloma

Exploring "bad luck" - why do some patients develop myeloid leukaemia?

Genomic sequencing to find AML-causing mutations

The latest in multiple myeloma: a European and US perspective

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia

Advances in the treatment and management of CLL

Transplantation combined with novel agents optimal treatment for multiple myeloma

Monoclonal antibodies and multiple myeloma

New definition for multiple myeloma improves patient outcomes

Factors influencing response to blinatumomab in relapsed/refractory ALL